Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -5.80% | -12.48% | +1.91% | +3.55% | +9.76% |
| Gross Profit Growth | -5.80% | -12.48% | +1.91% | +3.55% | +9.76% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.71% | +0.89% | +0.67% | +0.90% | +0.67% |
| Weighted Average Shares Diluted Growth | +0.71% | +0.89% | +0.67% | +0.90% | +0.67% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.64% | +2.11% | -79.43% | -82.19% | -78.85% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -18.64% | -21.90% | -24.52% | -25.47% | -5.49% |
| Book Value per Share Growth | -42.14% | -44.19% | -47.12% | -50.21% | +12.46% |
| Debt Growth | +0.58% | -5.97% | -8.43% | -11.06% | -12.70% |
| R&D Expense Growth | -23.96% | -21.13% | -5.33% | -22.64% | -24.58% |
| SG&A Expenses Growth | -22.23% | -20.00% | -25.47% | -29.09% | -29.87% |